Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2010 2
2011 2
2016 3
2017 1
2021 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Metabolic changes in the plasma of mild Alzheimer's disease patients treated with Hachimijiogan.
Kainuma M, Kawakatsu S, Kim JD, Ouma S, Iritani O, Yamashita KI, Ohara T, Hirano S, Suda S, Hamano T, Hieda S, Yasui M, Yoshiiwa A, Shiota S, Hironishi M, Wada-Isoe K, Sasabayashi D, Yamasaki S, Murata M, Funakoshi K, Hayashi K, Shirafuji N, Sasaki H, Kajimoto Y, Mori Y, Suzuki M, Ito H, Ono K, Tsuboi Y. Kainuma M, et al. Among authors: mori y. Front Pharmacol. 2023 Jun 12;14:1203349. doi: 10.3389/fphar.2023.1203349. eCollection 2023. Front Pharmacol. 2023. PMID: 37377927 Free PMC article.
An exploratory, open-label, randomized, multicenter trial of hachimijiogan for mild Alzheimer's disease.
Kainuma M, Ouma S, Kawakatsu S, Iritani O, Yamashita KI, Ohara T, Hirano S, Suda S, Hamano T, Hieda S, Yasui M, Yoshiiwa A, Shiota S, Hironishi M, Wada-Isoe K, Sasabayashi D, Yamasaki S, Murata M, Funakoshi K, Hayashi K, Shirafuji N, Sasaki H, Kajimoto Y, Mori Y, Suzuki M, Ito H, Ono K, Tsuboi Y. Kainuma M, et al. Among authors: mori y. Front Pharmacol. 2022 Oct 14;13:991982. doi: 10.3389/fphar.2022.991982. eCollection 2022. Front Pharmacol. 2022. PMID: 36313371 Free PMC article.
Kinetic information from dynamic contrast-enhanced MRI enables prediction of residual cancer burden and prognosis in triple-negative breast cancer: a retrospective study.
Yamaguchi A, Honda M, Ishiguro H, Kataoka M, Kataoka TR, Shimizu H, Torii M, Mori Y, Kawaguchi-Sakita N, Ueno K, Kawashima M, Takada M, Suzuki E, Nakamoto Y, Kawaguchi K, Toi M. Yamaguchi A, et al. Among authors: mori y. Sci Rep. 2021 May 12;11(1):10112. doi: 10.1038/s41598-021-89380-4. Sci Rep. 2021. PMID: 33980938 Free PMC article.
A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer.
Kanai M, Yoshimura K, Asada M, Imaizumi A, Suzuki C, Matsumoto S, Nishimura T, Mori Y, Masui T, Kawaguchi Y, Yanagihara K, Yazumi S, Chiba T, Guha S, Aggarwal BB. Kanai M, et al. Among authors: mori y. Cancer Chemother Pharmacol. 2011 Jul;68(1):157-64. doi: 10.1007/s00280-010-1470-2. Epub 2010 Sep 22. Cancer Chemother Pharmacol. 2011. PMID: 20859741 Free article. Clinical Trial.
A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer.
Kanai M, Yoshimura K, Tsumura T, Asada M, Suzuki C, Niimi M, Matsumoto S, Nishimura T, Nitta T, Yasuchika K, Taura K, Mori Y, Hamada A, Inoue N, Tada S, Yanagihara K, Yazumi S, Osaki Y, Chiba T, Ikai I, Fukushima M, Uemoto S, Hatano E. Kanai M, et al. Among authors: mori y. Cancer Chemother Pharmacol. 2011 Jun;67(6):1429-34. doi: 10.1007/s00280-010-1443-5. Epub 2010 Sep 2. Cancer Chemother Pharmacol. 2011. PMID: 20811895 Free article. Clinical Trial.